<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980068</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19120066</org_study_id>
    <secondary_id>5P01HL103455</secondary_id>
    <nct_id>NCT02980068</nct_id>
  </id_info>
  <brief_title>A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction</brief_title>
  <acronym>PMED</acronym>
  <official_title>An Open Label Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction (PH-HFpEF) and Normal Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gladwin, Mark, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-center study to examine distinguishing features of the&#xD;
      structure and function of the oral and gut microbiome in healthy adult normal volunteers&#xD;
      compared to volunteers with PH-HFpEF in the breakdown of oral nitrate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will enroll 60 Group II PH (PH-HFpEF) or Group I PAH patients and 60 matched healthy&#xD;
      controls over three years. The Subjects will receive a single dose of one of the two study&#xD;
      drugs, determined by whether they will participate in one study visit or two: 15N nitrate&#xD;
      (1,000 mg) or 14N Sodium Nitrate: standard sodium nitrate, and all will receive one dose of&#xD;
      CLA 3g. Twenty of the PH or PAH subjects and 20 of the control subjects willing to return for&#xD;
      a follow up visit 24 hours after drug administration will receive 15N nitrate. All others&#xD;
      will receive standard sodium nitrate. CLA will be obtained from GNC (General Nutrition&#xD;
      Corporation) and given once.&#xD;
&#xD;
      Throughout the experiment, we will measure blood pressure, heart rate, and respiratory rate&#xD;
      as well as co-oximetry. Plasma samples are collected at approximate times 0, 2, and 6 hrs&#xD;
      post-drug administration. Urine will be collected at approximate times 0 and 6 hrs. We will&#xD;
      examine plasma and urine nitrate and nitrite. The 40 subjects who return for a second visit&#xD;
      24 hours post-drug administration will provide an additional plasma and urine sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nitrate level in urine</measure>
    <time_frame>Urine collected approx 0 &amp; 6 hours after drug administration</time_frame>
    <description>The investigators will examine urine nitrate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nitrate level in plasma</measure>
    <time_frame>Approx 50cc of blood drawn approx 0, 2, &amp; 6 hours after drug administration</time_frame>
    <description>The investigators will examine plasma nitrate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial content of gut microbiome</measure>
    <time_frame>Stool collected before drug administration</time_frame>
    <description>Stool will be analyzed for bacterial makeup</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial content of the oral microbiome</measure>
    <time_frame>Saliva and tongue scraping will occur preceding administration of drug</time_frame>
    <description>Saliva and tongue scraping will be analyzed for bacterial makeup</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nitrite level in urine</measure>
    <time_frame>Urine collected approx 0 &amp; 6 hours after drug administration</time_frame>
    <description>The investigators will examine urine nitrite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nitrite level in plasma</measure>
    <time_frame>Approx 50cc of blood drawn approx 0, 2, &amp; 6 hours after drug administration</time_frame>
    <description>The investigators will examine plasma nitrite</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Frequently over 6 hour study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Continuous over 6 hour study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in respiratory rate</measure>
    <time_frame>Continuous over 6 hour study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin concentration</measure>
    <time_frame>Continuous over 6 hour study visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pulmonary; Hypertension</condition>
  <condition>Heart Failure</condition>
  <condition>Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>15N Nitrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14N Sodium Nitrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15N Nitrate</intervention_name>
    <description>1,000 mg/11.8 mmol, oral, on day one, hour zero</description>
    <arm_group_label>15N Nitrate</arm_group_label>
    <other_name>15N Sodium Nitrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14N Nitrate</intervention_name>
    <description>1,000 mg/11.18 mmol, oral, on day hour, hour zero</description>
    <arm_group_label>14N Sodium Nitrate</arm_group_label>
    <other_name>14N Sodium Nitrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION:&#xD;
&#xD;
          -  Male or female, 18 years of age or older&#xD;
&#xD;
          -  PH group: Pulmonary hypertension, hemodynamically defined by a mean PAP ≥ 25 mm Hg,&#xD;
             and a TPG &gt;= 12 at rest or during exercise as demonstrated on a right heart&#xD;
             catheterization in the last 10 years&#xD;
&#xD;
          -  RHC Control group: Normal hemodynamics (mean PAP &lt; 25 mm Hg, PCWP ≤ 15 mm Hg) on&#xD;
             clinical right heart catheterization&#xD;
&#xD;
          -  Healthy Control group: Healthy patients with no evidence of pulmonary hypertension,&#xD;
             respiratory or cardiac disease&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        EXCLUSION:&#xD;
&#xD;
          -  Use of systemic antibiotics and/or chlorhexidine mouthwash, within the previous three&#xD;
             months&#xD;
&#xD;
          -  Use of immune suppression (chemotherapy, oral prednisone greater than 20mg per day,&#xD;
             etc) with in the previous three months&#xD;
&#xD;
          -  Use of phosphodiesterase-5 inhibitors (tadalafil, sildenafil, etc) within 7 days&#xD;
             before study drug administration&#xD;
&#xD;
          -  Current pregnancy or lactation&#xD;
&#xD;
          -  Uncontrolled systemic hypertension based on repeated measurement of sitting systolic&#xD;
             blood pressure &gt;185 mm Hg or sitting diastolic blood pressure &gt;110 mm Hg at screening&#xD;
&#xD;
          -  Has chronic renal insufficiency as defined by serum creatinine &gt;3 mg/dL at screening&#xD;
             or requires dialytic support&#xD;
&#xD;
          -  Known history of left ventricular ejection fraction &lt; 40% by multiple gated&#xD;
             acquisition scan (MUGA), angiography, or echocardiography&#xD;
&#xD;
          -  History of atrial septostomy&#xD;
&#xD;
          -  Repaired or unrepaired congenital heart disease&#xD;
&#xD;
          -  Pericardial constriction&#xD;
&#xD;
          -  Restrictive or constrictive cardiomyopathy&#xD;
&#xD;
          -  Symptomatic coronary disease with demonstrable ischemia&#xD;
&#xD;
          -  Addition or change in dosing of hormonal contraception medications (OCP, IUD,&#xD;
             Depo-Provera) in the past 4 weeks.&#xD;
&#xD;
          -  Other severe acute or chronic medical or laboratory abnormality that may increase the&#xD;
             risk associated with study participation or investigational product administration,&#xD;
             that may interfere with the interpretation of study results and, in the judgment of&#xD;
             the investigator, would make the subject inappropriate for entry into this study or&#xD;
             would prevent completion of the study&#xD;
&#xD;
          -  Active participation in other research studies with investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nydia Chien, MSN, RN</last_name>
    <phone>412-647-2791</phone>
    <email>chienn@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nydia Chien</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nydia Chien, MSN, RN</last_name>
      <phone>412-647-2791</phone>
      <email>chienn@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alison Morris, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Morris, MD</last_name>
      <phone>412-624-8330</phone>
      <email>morrisa@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Alison Morris</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After de-identification, all participant data collected during the trial will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be made following publication.</ipd_time_frame>
    <ipd_access_criteria>Data will be available publicly.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

